Sponsor-Investigators
Hoosier Cancer Research Network is honored to collaborate with many thought leaders in clinical oncology research across the United States. The following sponsor-investigators have led […]
Hoosier Cancer Research Network is honored to collaborate with many thought leaders in clinical oncology research across the United States. The following sponsor-investigators have led […]
2014 was a year of rapid fire change and accomplishment for the Hoosier Cancer Research Network (HCRN). It’s all in a name … the Hoosier […]
Next Meeting See HCRN Calendar for schedule. Working Group Members Shilpa Gupta, MD (co-chair) — Cleveland Clinic Rana McKay, MD (co-chair) — University of California […]
Hoosier Cancer Research Network investigators recently presented an E-Poster on the HCRN study GU18-343 during the ESMO 2020 Virtual Congress. The multi-center clinical trial, “A […]
The University of Wisconsin Carbone Cancer Center became one of the first six comprehensive cancer centers designated by the National Cancer Institute in 1973. UW […]
Three HCRN investigator-initiated clinical trials were highlighted during the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting held virtually June 4-8. Deepak Kilari, MD, […]
Next Meeting See HCRN Calendar for schedule. Working Group Members Jonathon B. Cohen, MD, MS (co-chair) — Winship Cancer Institute of Emory University Natasha Galanina, […]
Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Cancer Research Network GU10-148
Following is a cumulative list of Hoosier Cancer Research Network publications in quality of life/cancer control.
Next Meeting See HCRN Calendar for schedule. Working Group Members Carey Anders, MD (co-chair) — Duke University Erica Stringer-Reasor, MD (co-chair) — University of Alabama […]
A new Hoosier Cancer Research Network study may help researchers determine whether the choice of chemotherapy regimens used in combination with the immunotherapy drug nivolumab […]
A Hoosier Cancer Research Network multi-site phase II study led by Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute is testing the poly (ADP-ribose) […]
Research cures cancer, and cancer is the top strategic priority of the Froedtert & the Medical College of Wisconsin. Its mission is to uncover the […]
Four Hoosier Cancer Research Network (HCRN) investigator-initiated clinical trials were highlighted during the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL. […]
This month, Hoosier Cancer Research Network features our member, the University of Wisconsin Carbone Cancer Center, and Christos Kyriakopoulos, MD, associate professor of medicine at […]
A Hoosier Cancer Research Network study for adult patients with muscle-invasive bladder cancer (MIBC) will help doctors determine whether some patients could forego bladder removal […]
Results from a Hoosier Cancer Research Network study in triple negative breast cancer, led by researchers at the Indiana University Melvin and Bren Simon Comprehensive […]
The Tisch Cancer Institute (TCI) at Mount Sinai, is a world-class translational cancer institute established in December 2007. TCI has recruited more than 30 acclaimed […]
A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE) Status: Open to Accrual
Next Meeting See HCRN Calendar for schedule. Working Group Members Gregory A. Durm, MD (co-chair) — Indiana University Ryan Gentzler, MD (co-chair) — University of […]
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter